Teachers Advisors LLC lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 24.6% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,772 shares of the biopharmaceutical company’s stock after buying an additional 30,750 shares during the period. Teachers Advisors LLC owned approximately 0.13% of ACADIA Pharmaceuticals worth $4,344,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also bought and sold shares of ACAD. Nationwide Fund Advisors purchased a new position in shares of ACADIA Pharmaceuticals in the first quarter worth about $424,000. Russell Investments Group Ltd. increased its position in ACADIA Pharmaceuticals by 379.7% during the first quarter. Russell Investments Group Ltd. now owns 24,150 shares of the biopharmaceutical company’s stock worth $831,000 after purchasing an additional 19,116 shares during the last quarter. Bank of New York Mellon Corp increased its position in ACADIA Pharmaceuticals by 5.6% during the first quarter. Bank of New York Mellon Corp now owns 396,646 shares of the biopharmaceutical company’s stock worth $13,636,000 after purchasing an additional 21,191 shares during the last quarter. UBS Asset Management Americas Inc. increased its position in ACADIA Pharmaceuticals by 2.8% during the first quarter. UBS Asset Management Americas Inc. now owns 710,367 shares of the biopharmaceutical company’s stock worth $24,422,000 after purchasing an additional 19,024 shares during the last quarter. Finally, Karp Capital Management Corp acquired a new stake in ACADIA Pharmaceuticals during the first quarter worth about $720,000. 97.10% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Teachers Advisors LLC Boosts Stake in ACADIA Pharmaceuticals Inc. (ACAD)” was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://sportsperspectives.com/2017/10/13/teachers-advisors-llc-boosts-stake-in-acadia-pharmaceuticals-inc-acad.html.
Several equities research analysts recently issued reports on the stock. ValuEngine upgraded shares of ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 10th. Zacks Investment Research cut shares of ACADIA Pharmaceuticals from a “buy” rating to a “sell” rating in a research report on Monday, July 17th. BidaskClub upgraded shares of ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Leerink Swann restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research report on Monday. Finally, HC Wainwright restated a “buy” rating and set a $60.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Thursday, October 5th. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $46.21.
In other news, EVP Glenn Baity sold 14,322 shares of the stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $34.88, for a total transaction of $499,551.36. Following the transaction, the executive vice president now directly owns 78,578 shares in the company, valued at approximately $2,740,800.64. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 116,426 shares of company stock worth $4,100,885. Insiders own 22.25% of the company’s stock.
Shares of ACADIA Pharmaceuticals Inc. (ACAD) opened at 35.50 on Friday. The firm’s market capitalization is $4.35 billion. The firm’s 50 day moving average is $36.58 and its 200-day moving average is $31.73. ACADIA Pharmaceuticals Inc. has a 12 month low of $20.68 and a 12 month high of $41.20.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.72) by $0.17. The business had revenue of $30.50 million for the quarter, compared to analyst estimates of $20.02 million. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The company’s revenue was up 30400.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.63) EPS. On average, analysts expect that ACADIA Pharmaceuticals Inc. will post ($2.55) EPS for the current fiscal year.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).
Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.